.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Immunotherapy has revolutionized the oncology landscape. However, resistance remains a significant hurdle in gastric cancer treatment. A new study introduces a machine learning model to predict gastric cancer immunotherapy response. This model utilizes single-cell transcriptomics to identify specific cellular determinants of resistance.
The research identifies a unique T/NK cell subset associated with poor outcomes. These cells exhibit impaired MHC-I-mediated immune recognition. Furthermore, they display elevated histidine metabolism and stay at an early differentiation stage. Consequently, these findings offer a new map of the tumor microenvironment. Understanding these cell populations is crucial for refining treatment protocols.
The study highlights the transcription factor IRF1 as a potential suppressor of resistance. Mechanistically, IRF1 inhibits invasion and promotes cancer cell death through apoptosis. Additionally, the developed machine learning model predicts patient responses accurately across two independent cohorts. Notably, the model achieved AUCs of 0.75 and 0.73. Therefore, these insights may guide future personalized therapy strategies. Targeting the T/NK cell subset or restoring IRF1 function represents a promising approach to overcoming resistance.
IRF1 acts as a suppressor of immune resistance. It works by inhibiting the invasion of cancer cells and promoting apoptosis, which enhances the effectiveness of immunotherapy.
The model analyzes single-cell transcriptomic data to identify T/NK cell subsets and metabolic markers. It reached predictive accuracy with AUCs of 0.75 and 0.73 in independent patient groups.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Ning W et al. A Single-Cell Guided Machine Learning Model Predicts Response to Immune Checkpoint Inhibitors in Gastric Cancer. J Chem Inf Model. 2026 Jun 11. doi: 10.1021/acs.jcim.6c01090. PMID: 42273856.
Sun K et al. Single-cell transcriptomics in cancer immunotherapy. Journal of Hematology & Oncology. 2024;17(1):15-28.
Chen W et al. IRF1 suppresses gastric tumorigenesis via dual PI3K/AKT-ERK pathway modulation. Cell Oncol (Dordr). 2026 Jan 13;49(1):24. doi: 10.1007/s13402-025-01134-w.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a single-cell guided machine learning model to predict gastric cancer response to immunotherapy. By identifying IRF1 as a key suppressor of resistance and profiling T/NK cell subsets, the study provides a robust tool for personalizing treatment and overcoming drug resistance.
last month
Researchers at SGPGIMS Lucknow have isolated and cultured human heart valve interstitial cells from donor tissues. This milestone advances understanding of rheumatic heart disease pathways like TGF-beta/SMAD3 and ERK1/2, laying the foundation for tissue-engineered heart valves and drug testing.
Today
Johnson & Johnson announced a $5.5 billion settlement to resolve nearly 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. This comprehensive deal covers 99.75% of active claims. Read about the legal strategy, scientific evidence on talc exposure, and clinical counseling for patients.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
4 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
4 days back
Deepinder Goyal's healthtech startup Temple is raising capital at a $500 million valuation and pricing its temporal wearable at Rs 80,000. Worn on the side of the forehead, the device tracks microvascular blood flow and real-time Entropy to monitor physiological stress, metabolic expenditure, and recovery.
Today
